PwC

future forward-looking 2026 new year
Biotech

Pharma's 'urgent need for reinvention': PwC's call to action

PwC has laid out bold ambitions for what it believes drugmakers could achieve by 2035, as well as steps those companies should start taking in 2026.
Fraiser Kansteiner Jan 8, 2026 6:00am
puzzle pieces merger and acquisition business concept

Pharma and life sci M&A volume dropped 8% in 2024: PwC

Dec 12, 2024 5:00am
MA gears up growth mergers buyout strategy

Biopharma dealmaking still rising, but M&A value steady: PwC

Jun 20, 2024 8:27am
open window window winter

Biotech IPO window will ‘gradually reopen’ in 2024: PwC

Dec 14, 2023 9:39am
2023 2022 year ahead prediction forecast

M&A values halve, volumes plunge. Will we ever see deals again?

Dec 8, 2022 8:25am
concept of chess board with letters MA

Expect a 'buoyant year' in biopharma M&A with $1.7T to deploy

Feb 15, 2022 8:00am